Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Stocks in this Quantisnow insightHealth Care
Historical context for APVO
Across the 20 sessions after earlier APVO headlines, the stock closed higher 5 times and lower 14 times, with a median move of 4.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | APVO | SPY |
|---|---|---|---|
| Oct 14, 2026 | Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting | +0.0% | -1.1% |
| Sep 24, 2026 | Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development | -3.2% | -0.1% |
| Sep 3, 2026 | Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | -34.2% | +1.0% |
| Aug 14, 2026 | Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Resultsand 1 other headline that session | -13.5% | -0.2% |
| Aug 12, 2026 | Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds | -15.4% | +0.3% |
| Jul 27, 2026 | Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone | -4.1% | +0.0% |
Quantisnow market dataNASDAQ
APVO
Aptevo Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for APVO
Full APVO profile on Quantisnow Follow APVO and get a push notification the moment its next story breaks.